Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Company facts
| Company | Acumen Pharmaceuticals, Inc. |
|---|---|
| Symbol | ABOS |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $206.83M (Massive market data, 2026-09-10) |
| Employees | 61 |
| Country | United States |
| Website | https://acumenpharm.com |
Trading — Acumen Pharmaceuticals, Inc.
| Last price | $2.92 |
|---|---|
| Change | 2.10% |
| Previous close | $2.86 |
| Day range | $2.84 – $2.98 |
| 50-day average | $2.61 |
| 200-day average | $2.47 |
| Average volume | 477,726 |
Price basis: yfinance_daily_bar_close · 2026-09-11T21:07:44.986755+00:00
Valuation and financial health
| Earnings per share | $-1.45 |
|---|---|
| Price / book | 3.61 |
| Enterprise value / EBITDA | -1.70 |
| Debt / equity | 0.55 |
| Current ratio | 2.47 |
| Dividend yield | 0.00% |
| Free cash flow | -$91.79M |
| Cash ratio | 1.27 |
| Enterprise value | $178.95M |
Reported 2026-09-10
Earnings
| Report date | 2026-11-11 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | 2026-09-30 |
| EPS estimate | -0.43 |
Source: optionsai supplemental public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ABOS are on the IntelTrends dashboard.